Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Assess the Drug-Drug Interaction Potential of a Single 1200 mg IV Dose of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects.

NCT02340988 is registered in ClinicalTrials.gov with Melinta Therapeutics, Inc. as lead sponsor.

NCT NCT02340988
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02340988 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Assess the Drug-Drug Interaction Potential of a Single 1200 mg IV Dose of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects.
Lead sponsor
Melinta Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2015
Completion date
September 30, 2015
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy